Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
Metrics: PDF 956 views | HTML 1843 views | ?
Amos Toren1, Tatyana Pismenyuk1, Michal Yalon1, Shani Freedman1, Amos J. Simon1, Tamar Fisher1, Itai Moshe1, Juergen K.V. Reichardt2, Shlomi Constantini3, Yael Mardor4, David Last4, David Guez4, Dianne Daniels4, Moria Assoulin4, Ruty Mehrian-Shai1
1Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Tel Hashomer Affiliated to The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
2YachayTech University, Urcuquí, Ecuador
3Department of Pediatric Neurosurgery, Dana Children’s Hospital, Tel-Aviv-Sourasky Medical Center, Israel
4The Advanced Technology Center, Sheba Medical Center, Tel Hashomer Affiliated to The Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel
Ruty Mehrian-Shai, email: Ruty.Shai@sheba.health.gov.il
Keywords: glioblastoma multiforme, temozolomide, chemosensitivity, proliferation, zinc
Abbreviations: GBM: Glioblastoma multiforme; TMZ: Temozolomide; ZnCl2: Zinc chloride
Received: May 30, 2016 Accepted: July 19, 2016 Published: August 19, 2016
Temozolomide (TMZ) is an alkylating agent that has become the mainstay treatment of the most malignant brain cancer, glioblastoma multiforme (GBM). Unfortunately only a limited number of patients positively respond to it. It has been shown that zinc metal reestablishes chemosensitivity but this effect has not been tested with TMZ. Using both in vitro and in vivo experimental approaches, we investigated whether addition of zinc to TMZ enhances its cytotoxicity against GBM. In vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased with addition of zinc and this response was accompanied by an elevation of p21, PUMA, BAX and Caspase-3 expression and a decrease in growth fraction as manifested by low ki67 and lower colony formation. Analysis of GBM as intracranial xenografts in athymic mice and administration of concurrent TMZ and zinc yielded results consistent with those of the in vitro analyses. The co-treatment resulted in significant reduction in tumor volume in TMZ/zinc treated mice relative to treatment with TMZ alone. Our results suggest that zinc may serve as a potentiator of TMZ therapy in GBM patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.